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ation of cytosine residues in the expanded (CGG) triplet
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1Department of Pharmacology tein (RBP) containing two hnRNP K homology (KH) do-
mains and a single RGG cluster that exhibit affinity forDepartment of Psychiatry
University of Pennsylvania School of Medicine a number of mRNAs (Brown et al., 1998, 2001; Sung et
al., 2000), including its own (Ashley et al., 1993). ThePhiladelphia, Pennsylvania 19104
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University of Illinois domains of the FMR1 gene sufficient to cause symptoms
comparable to or more severe than the full mutationUrbana-Champaign, Illinois 61801
3 DNA Array Unit associated with the CGG repeat expansion supports the
involvement of the Fmr1 gene as the primary causativeGerontology Research Center
National Institute on Aging factor in the pathogenesis of FXS (De Boulle et al., 1993).
However, the mechanism by which the inactivation of aNational Institutes of Health
Baltimore, Maryland 21224 single X-linked gene can result in the sequelae of cogni-
tive deficits and secondary clinical abnormalities is not4 W.M. Keck Center for Comparative and Functional
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Characteristically, FMRP is found predominantly inUniversity of Illinois
Urbana-Champaign, Illinois 61801 neurons of synapse-rich tissue such as the hippocam-
pus and cerebellum within the central nervous system5 Centre for Neuroscience Research
Department of Neurology and Neurosurgery (CNS). Although it is principally cytoplasmic, it contains
nuclear localization and export signals, suggesting thatMcGill University
Montreal, Quebec H3A 2B4 it is capable of shuttling from the nucleus to the cyto-
plasm (Devys et al., 1993; Bardoni et al., 1997). There,Canada
it is known to interact preferentially with actively
translating polyribosomes (Corbin et al., 1997) in an
mRNP complex containing FXR1P and FXR2P (SchenckSummary
et al., 2001), nucleolin (Ceman et al., 1999), Y box pro-
teins (Ceman et al., 2000), and other FMRP-interactingThe Fragile X mental retardation-1 (Fmr1) gene encodes
proteins (Bardoni et al., 1999; Schenck et al., 2001). Itsa multifunctional protein, FMRP, with intrinsic RNA
role in suppressing translation (Laggerbauer et al., 2001;binding activity. We have developed an approach, anti-
Li et al., 2001) at the synapse in the absence of properbody-positioned RNA amplification (APRA), to identify
synaptic input (Weiler et al., 1997), in the context of thethe RNA cargoes associated with the in vivo configured
presence of immature dendritic spines in the neocortexFMRP messenger ribonucleoprotein (mRNP) complex.
of FXS autopsy patients (Rudelli et al., 1985) and Fmr1Using APRA as a primary screen, putative FMRP RNA
null mice (Comery et al., 1997) suggests that FMRP maycargoes were assayed for their ability to bind directly
have profound effects upon synaptic development andto FMRP using traditional methods of assessing RNA-
maturation in the CNS. Indeed, Drosophila FXS modelsprotein interactions, including UV-crosslinking and fil-
exhibit a phenotype that is consistent with this hypothe-ter binding assays. Approximately 60% of the APRA-
sis (Zhang et al., 2001a; Morales et al., 2002). Thesedefined mRNAs directly associate with FMRP. By ex-
observations have prompted several groups to searchamining a subset of these mRNAs and their encoded
for RNA cargoes associated with FMRP.proteins in brain tissue from Fmr1 knockout mice, we
Various strategies have been devised to identify thehave observed that some of these cargoes as well as
native targets of proteins displaying RNA binding activitythe proteins they encode show discrete changes in
(Trifillis et al., 1999; Tenenbaum et al., 2000). Althoughabundance and/or differential subcellular distribution.
these techniques have been successful at identifying anThese data are consistent with spatially selective reg-
apparent subset of the mRNAs associating with FMRP,ulation of multiple biological pathways by FMRP.
they utilize coimmunoprecipitation (co-IP) or other in
vitro assays to assess the FMRP RNA targets (BrownIntroduction
et al., 1998, 2001; Darnell et al., 2001). Here, we have
developed a methodology, antibody-positioned RNAThe most frequent inherited form of mental retardation
amplification (APRA), which can be used directly onis fragile X syndrome (FXS; Turner et al., 1996). It most
neurons in situ, permitting the identification of the mRNA
cargoes for FMRP or any RBP within an in vivo config-*Correspondence: eberwine@pharm.med.upenn.edu
6 These authors contributed equally to this work. ured mRNP complex. Using hippocampal neurons, we
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have used APRA followed by more traditional in vitro network are close to the site of anti-Tau mAb binding
and within proximity of the priming oligo. Taken to-assays to define a subset of mRNAs that are direct
gether, these data highlight the selectivity of the 1C3substrates of FMRP RNA binding activity in vivo. These
mAb APRA results.RNA cargoes encode proteins with diverse physiological
A potential concern with the use of the 1C3 mAb wasproperties. For a subset of RNAs exhibiting affinity for
its reported potential to crossreact with FXR1P in vitroFMRP, the mRNA and protein abundance and subcellu-
(Zhang et al., 1995) and to a lesser degree in intact cellslar distribution at a single developmental time point was
(Tamanini et al., 1999). To address this concern, wedetermined in a Fmr1 knockout (KO) mouse model.
performed APRA using a polyclonal antibody (2107) that
specifically recognizes FXR1P (Tamanini et al., 1997).Results
Here, we present a sampling of both 1C3 and 2107
APRAs (Figure 1E). We have observed some overlapIdentification of In Vivo RNA Cargoes by APRA
with the 1C3 results in all grids on the Neuroarray, andTo identify the subset of mRNAs that are substrates of
thus the presence of similar RNA binding domains inthe intrinsic RNA binding activity of FMRP, we devel-
FXR1P suggests that some cargoes of FMRP may beoped a method to identify the mRNAs associated with
targets of the intrinsic RNA binding activity of the FXR1P.the FMRP mRNP complex in its in vivo configuration (Fig-
Overall, analysis of all grids on the Neuroarray show thature 1A). To this end, a single-stranded priming/amplifi-
52% (116/223) of the genes identified as candidatecation oligo containing a spacer arm at the 5 end fol-
cargoes by 1C3 APRA are also positive with 2107 APRA.lowed by a restriction site, a T7 RNA polymerase pro-
The APRA positives shown in Figure 1E that are specificmoter, a linker sequence, and 15 degenerate nucleo-
for FMRP are DNA repair protein XRCC1 (row10col-tides at its 3 end was covalently coupled (Zhang et al.,
umn8), serum response factor (r9c11), and glutathione2001b) to anti-FMRP monoclonal antibody (mAb) 1C3
peroxidase 2 (r12c8). Those that are APRA positive for(Sittler et al., 1996). When the mAb-DNA complex is
both FMRP and FXR1P include Rab 8 (r8c11), bFGF2applied to primary cultured hippocampal neurons
(r11c8), and vascular cell adhesion molecule 1 (r11c11).(Buchhalter et al., 1990), the mAb positions the degener-
Also represented in this figure are mRNAs that are onlyate primer in proximity to mRNAs sequestered in the
2107-APRA positive, including cytochrome P450 sub-FMRP mRNP complex. 1C3 mAb staining before and
family IIB (r8c8), -integrin (r8c9), major vault proteinafter covalent attachment of the priming oligo confirm
(r8c12), protein phosphatase 1 inhibitor 2 (r11c9), Br-similar patterns of immunoreactivity (Figure 1B). The 3
cadherin (r11c10), Cys- and Gly-rich protein 3 (r11c12),degenerate nucleotide sequence on the mAb-attached
and chapsyn-110 (r12c10). More importantly, the quali-oligo primes the in situ transcription (Tecott et al., 1988)
tative pattern is largely distinct, suggesting that the 1C3of those mRNAs with accessible sequences not masked
and 2107 Abs will identify FMRP and FXR1P cargoes inby the mRNP complex. After cDNA synthesis, the mAb-
a specific manner. It is possible that FMRP and FXR1PcDNA complex is removed from the cells, and second-
exist in close proximity to one another in the mRNPstrand cDNA synthesis is completed in vitro. The double-
complex. Should the oligo on the selective 1C3 mAb
stranded cDNA is then removed from the mAb-cDNA
bind to RNAs associated with the other RBPs, then some
complex by restriction enzyme digestion, and the popu-
FXR1P cargoes could be scored as putative FMRP car-
lation of cDNAs is amplified by the antisense RNA ampli-
goes and vice versa. Similar concerns exist for the co-
fication procedure (Eberwine et al., 2001) where it can be
IP protocols where multiple RBPs may be part of the
used to screen macro- or microarrays. Here, we utilized co-IP complexes. We address a direct FMRP-mRNA
Neuroarrays containing 1100 human cDNAs that are interaction using two different binding assays, the re-
known to encode mRNAs expressed in the CNS (Figure sults of which are discussed in the next section.
1C). To complement the limited number of cDNA targets on When positioned on the FMRP mRNP, variations in
the Neuroarray, we have used Research Genetics GF300 the length of the priming oligo might be an important
macroarrays containing 5000 rat cDNAs (Figure 1D). determinant in accessing mRNA sequences. Shorter
When a mouse IgG1 control antibody that should not oligo sequences should prime RNAs more proximal to
bind to any native murine proteins is conjugated with the site of 1C3 mAb binding. In contrast, longer oligos
the long oligo and applied to the primary cultures, we are could provide greater access to mRNA sequences that
not able to detect any positive signals on the Neuroarray may be more distant from the site of binding or may be
with APRA analysis (Figure 1C). These data are repro- more successful at navigating around components of
duced when FMRP without a priming oligo is used in the mRNP complex that might sterically block the short
APRA analysis (data not shown). When a mAb to another priming oligo from accessible mRNA sequences. 1C3
cytoplasmic protein, nonphosphorylated Tau protein mAb was conjugated to either short (84 nt) or long (122
(Sperber et al., 1995), which is not a known component nt) oligos. These lengths were arbitrarily chosen and
of the FMRP mRNP, is conjugated to the long oligo, longer oligos are difficult to make using standard DNA
macroarray results generated by the anti-Tau mAb synthesis chemistry. From experiment to experiment,
APRA reveal a qualitatively different pattern of hybridiza- there was, on average,5% variation in the genes iden-
tion compared to the 1C3 APRA (Figure 1C), with anti- tified using 1C3 conjugated to the short oligo. These
Tau APRA showing approximately 117 positives with data were comparable to 1C3 conjugated to the long
only17% of these anti-Tau positives also being FMRP- oligo where variation from experiment to experiment
APRA positive. Since Tau is a primary component of the was also, on average, 5% (see Supplemental Figure
microtubule network and lacks any known intrinsic RNA S1 at http://www.neuron.org/cgi/content/full/37/3/
binding activity, these data suggest that some RNA- 417/DC1). Raw data for the IC3-short and IC3-long APRA
analysis are presented in Supplemental Figure S2. Com-containing mRNPs traversing the intracellular transport
In Vivo FMRP RNA Cargoes
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Figure 1. APRA Methodology and FMRP Macroarray Data
(A) Antibodies were conjugated to an oligo containing a restriction site 5 to the T7 RNA polymerase consensus sequence and terminating in
a 15 degenerate nucleotide sequence at its 3 end. The antibody was applied to fixed and permeabilized cells from primary cultures. First-
strand cDNA synthesis was performed in situ with antibodies positioning the oligo in close proximity to RNA sequences accessible to interaction
with the degenerate nucleotide sequence at the 3 end of the oligo (black bar). The Ab-DNA complex is then removed from the cells in primary
culture, and second-strand cDNA synthesis (red bar) is done in vitro. Double-stranded DNA is removed from the Ab by restriction digestion
and is then processed through two rounds of aRNA amplification with the second aRNA reaction incorporating 33P-radionuclides prior to
screening cDNA macroarrays.
(B) Immunostaining with 1C3 mAb before DNA attachment and following DNA attachment show similar staining distribution and intensity at
equivalent dilutions. Note the mainly neuronal labeling of the 1C3 antibody. Scale bar equals 15 m.
(C) Following processing, 33P-radiolabeled aRNA was applied to Neuroarrays. Consequently, true positives should hybridize in the same
manner on each half of the array (compare left side to right side). Representative results using the long oligo or short oligo with either 1C3
mAb (n  6), mouse IgG1 (n  3), or anti-tau mAb (n  3) are shown.
(D) One field of a representative GF300 macroarray illustrates the signal distribution pattern obtained for probes generated by 1C3 APRA (n  3).
(E) Comparison of the lower left quadrant of Grid 6 between 1C3 (1C3 mAb) and anti-FXR1P (2107 pAb; n  2). Red circles highlight candidate
FMRP cargoes and the reciprocal grid location in an anti-FXR1P APRA. These data demonstrate discernible differences with some overlap
between mRNA targets of FXR1P and FMRP.
(F) Neuroarray analysis generated with the short oligo (n  3) and the long oligo showed distinct differences in those RNA cargoes in proximity
to the FMRP complex. Red circles highlight differences in these macroarray analyses.
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parisons between the set of targets identified by 1C3- Purine Quartet Analysis of FMRP-Associated
RNA Cargoeslong and 1C3-short APRAs show a similar pattern of
identified genes with only a marginally higher (9%) num- Using a Perl script we developed based on regular ex-
pression motif search, we searched for the consensusber of putative cargoes identified by the long oligo (Fig-
ure 1F). These data suggest that a majority of the mRNAs sequence (DDGG-N(0-2)-DDGG-N(0-2)-DDGG-N(0-2)-DDGG,
where D is any nucleotide except C) believed to besequestered in or near the FMRP mRNP have accessible
sequence within the relatively small distance of the short recognized by FMRP (Schaeffer et al., 2001; Darnell et
al., 2001). Of the 83 APRA-positive clones, one or morepriming oligo.
copies of the G-quartet motif were present in 18 cargoes
(Table 2). Six more contain a highly similar G-quartet
motif with a spacer region (N) of 3 nucleotides instead ofSecondary In Vitro Assays Confirm Direct
Interactions with FMRP 0–2 denoted above. However, it is unclear if this change
would disrupt the secondary structure required to formThe APRA-defined FMRP positives (see Experimental
Procedures) were interpreted as putative in vivo targets the G-quartet structure. This analysis shows that while
some FMRP targets do indeed contain G-quartet motifs,of the RNA binding activity of FMRP. We observe19%
of the cDNAs on the Neuroarray (223/1153) and 16% there appear to be other cis-acting sequences in FMRP
cargoes that confer binding to FMRP.on the GF300 macroarrays (818/5000) meet this criteria.
We next asked whether these putative in vivo targets
could directly associate with FMRP. We performed two FMRP Cargoes Show Altered Subcellular Distribution
classical tests to assess the ability of individual mRNAs and Abundance in Fmr1 Null Mice
to bind to a RBP: filter binding assays (FBA) and UV Next, we examined the impact of Fmr1 gene silencing
crosslinking (UVX). Eighty-three of the initial positives (The Dutch-Belgian Fragile X Consortium, 1994) on the
from the Neuroarray screen were evaluated in this man- RNA distribution and abundance for a small subset of
ner. We present a subset of 1C3 APRA positives that these FMRP cargoes at a single developmental time
are representative of the differences in intensity in hy- point. In situ hybridization (ISH) was performed on para-
bridization signal and the diversity of functional ele- saggital sections from wild-type (wt) and Fmr1 KO mice
ments encoded by these putative mRNAs cargoes (Fig- (Figures 3 and 4) to determine changes in subcellular
ure 2A). For these experiments, recombinant FMRP localization of the corresponding RNAs at age P15.
(Figure 2B) was incubated with in vitro transcribed, ra- Three general patterns were observed in these studies.
diolabeled cRNA. Samples were then processed for the In the first, the loss of FMRP does not appear to alter
ability to bind to nitrocellulose filters (FBA) or migrate the subcellular distribution of the G protein-coupled re-
on a denaturing polyacrylamide gel at the appropriate ceptor kinase 4 (GRK 4) and Cu/Zn superoxide dismu-
MW following RNase digestion of the UV-crosslinked tase 1 (SOD 1) within the Purkinje cells of the cerebellum,
FMRP-RNA complex (UVX). When assessed for their where a majority of the signal is confined to the soma
ability to bind FMRP directly in FBAs (Figure 2C; see in wt and KO mice. The second pattern, exemplified
Supplemental Figure S3 at http://www.neuron.org/cgi/ by RGS5 and dystroglycan-associated glycoprotein 1
content/full/37/3/417/DC1), a subset of the target tran- (DAG1) mRNA, shows a change in the distribution of
scripts, such as ribosomal protein L13a RNA, bound to the signal in KO mice. Here, dendritic staining in the
FMRP at less than 20% relative to the binding of FMRP hippocampus (molecular layer) is largely absent follow-
to Fmr1 RNA. The use of Fmr1 RNA binding to FMRP ing the loss of FMRP. High-power views clearly show
protein is a convenient standard used in the field since the dendritic localization of these mRNAs. These images
Fmr1 mRNA was the only known specific RNA cargo for are not as uniform as the lower-magnification images
FMRP for several years. In the UVX assay (Figure 2D; due to the refractive properties of imaging through a
see Supplemental Figure S3), we observed that RNAs tissue section. Finally, the ribosomal component p40/
that displayed higher relative binding in FBAs, such as LRP (Auth and Brawerman, 1992) ISH demonstrates the
RGS5, RGS12, and RGS 13, routinely would yield migrat- third pattern in which no change is observed in the
ing complexes at a slightly higher molecular weight than dendritic distribution in the KO mice. This pattern is
the recombinant FMRP. In no cases with mRNA binding present for several other FMRP cargoes including CDK4,
at less than 20% of FMRP mRNA binding to FMRP was GABAA receptor  subunit, -fodrin, gankyrin, -adaptin,
a protein complex observed migrating at the appropriate and Oculocerebrorenal syndrome of Lowe (OCRL) (Fig-
molecular weight in UVX assays. Of the APRA positives, ure 5). As shown previously (Steward et al., 1998), it
60% were positive in the FBA and UVX assays, 13% appears that there is no change in MAP2 mRNA localiza-
were positive in only the FBA, and 27% were negative tion in this mouse model of FXS.
in both in vitro assays (Table 1). For the most part, we We next sought to determine whether the FMRP car-
used full-length mRNA for these binding studies, but in goes are altered in abundance in KO mice relative to wt
a few cases, the full-length clone was unavailable. We mice by Northern blot analysis (Figure 5A). Total RNA
cannot exclude the possibility that some of our negative from the cortex of wt or KO mice was probed with radio-
results are due to the fact that the sequence required labeled cDNA corresponding to DAG1 or p40/LRP
for binding was not present in the synthesized cRNA. To mRNA. The reduced abundance of these two mRNAs
our knowledge, no comparable large-scale verification in the absence of FMRP mirrors the changes observed
with targets derived from micro- or macroarray analysis with ISH. It is unclear how these data may differ at other
has been presented in other studies of FMRP-associ- ages, as these data reflect RNA isolated from P14–P16
animals.ated RNA cargoes.
In Vivo FMRP RNA Cargoes
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Figure 2. In Vivo Isolated FMRP Cargoes and Their Secondary In Vitro Screens
(A) Regions of the Neuroarrays showing the hybridization of selected cDNAs to APRA generated probes are shown. The red circles highlight
the particular clones tested for the ability to bind directly to recombinant FMRP (characterized in B), in FBAs (see C), and UVX (see D) assays.
(B) 10 g (lane 1) or 1 g (lanes 2 and 3) of recombinant myc-tagged FMRP run on 8% SDS-PAGE gels and transferred to nitrocellulose
membranes. Lane 1 is stained with amido black; lane 2 is probed with a polyclonal Ab against FMRP (KI Ab); lane 3 has been probed with
antibody against the c-myc epitope. Molecular weight markers are indicated at the left (M).
(C) The FBA data are presented as normalized to Fmr1 mRNA binding to FMRP as 100% (n  5).
(D) Recombinant FMRP UV-crosslinked to RNA runs at 80 kDa on this Novex protein gel (n  3–5).
To expand upon these data, we performed real-time significant measurable difference by real-time PCR with
the message reduced 3- to 4-fold in the KO preparationsPCR on hippocampal RNA from four KO and four wt
mice for nine FMRP bound mRNAs. Those tested include (Figure 5B). Taken together, these data suggest that
FMRP may affect both abundance and localization of-adaptin, ADP ribosylation-like factor (ARL3), CDK4,
FK506 binding protein 3 (FKBP25), -Fodrin, GRK4, p28/ its RNA cargoes.
gankyrin, RGS5, and SOD1, all of which were compared
to the signal obtained from -actin. Because whole hip- RNA Cargo-Encoded Proteins Are Redistributed
in Subcellular Fractions in Fmr1 Null Micepocampi were used to isolate RNA, we did not expect
to see a marked difference in the levels of transcript To evaluate whether the changes in RNA distribution
and abundance were associated with changes in proteinpresent for each mRNA tested. Only GRK4 showed a
Neuron
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Table 1. Results of FMRP RNA Cargoes Tested for Direct Interactions with FMRP
FMRP-associated RNA cargoes are grouped into functional classes with the gene name, IMAGE IDs, and genetic locus. mRNAs with asterisks
indicate the GenBank accession number. Plus and minus signs show whether the mRNA was positive or negative in FBA or UVX assays. For
the FBAs (n  3–6 trials for each RNA) greater than 20% of control binding corresponds to positive (see Experimental Procedures). For UVX
assays (n  2–4 trials for each RNA), positives denote the presence of a band migrating at 80 kDa in PAGE. The genetic locus for each of
these APRA positives is presented and where present cosegregating autism loci are shown.
levels, we analyzed the protein levels from total protein antibodies (we have not tested GRK2 in our FMRP RNA
binding assays), since there is significant sequence ho-lysates and synaptically enriched synaptoneurosomal
lysates from the cortex of wt and FMRP KO mice of nine mology between these two proteins and we wanted to
ensure that we could distinguish the influence of FMRPof the FMRP mRNA cargoes (glucocorticoid receptor 
[GR], GRK4, SOD, RGS5 and DAG1 [both - and -forms on either one. This is complemented by the data showing
no difference in the protein abundances for -DAG,shown], the immature [40 kDa] and mature [68 kDa]
isoforms of p40/LRP [only the 40 kDa form is shown], which is processed from the same protein precursor as
-DAG. The reduction in CDK4 and RGS5 protein inCDK4, -fodrin, and gankyrin; Figure 6). We assumed
that a KO-wt difference in total lysates would reflect synaptic areas with no detectable change in the total
cellular lysate suggests a selective reduction in the tar-differential overall protein expression, while a difference
in synaptoneurosomes, not mirrored in total protein ly- geting of these proteins to synaptic areas. These data
suggest changes in subcellular distribution of some ofsate levels, would indicate differential protein localiza-
tion within the cell. This analysis indicated a difference the proteins encoded by FMRP mRNA cargoes with
diminution of protein levels in synaptically enriched ar-in total lysate values for GRK2 and -DAG1 and a differ-
ence in synaptoneurosome values for GRK2, CDK4, and eas. GR and SOD did not differ in either preparation,
showing that there is not a generalized decrease in syn-RGS5. -DAG shows a different distribution with a de-
crease in total amount of protein but no change in synap- aptoneurosome protein abundances in the cortex of KO
animals.tically localized DAG1. In combination with the DAG1
mRNA decrease observed earlier, this suggests a com- It is important to note in discussing protein abun-
dances, mRNA abundances, and mRNA subcellular dis-pensatory pathway to sustain basal levels in perisynap-
tic areas. We chose to examine both GRK4 and GRK2 tribution that the measurements that were done used
In Vivo FMRP RNA Cargoes
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Figure 3. Differential ISH of FMRP RNA Cargoes between Wild-Type and Fmr1 KO Mice
ISH of FMRP RNA cargoes was performed in parasaggital sections of Fmr1 KO and wt mice using immunoflurorescence. The cerebellar
regions (6 magnification) and the CA1 region of the hippocampus (20 magnification) highlight the changes observed in the patterns of
distribution of these mRNAs in wt and FmR1 KO mice. The Purkinje cell layer (PCL) and the granule cell layer (GCL) of the cerebellum are
indicated. In the hippocampus, the pyramidal cell layer contains primarily cell soma (red brackets) while the molecular layer is enriched in
dendrites (black brackets) elaborated from pyramidal cell perikarya. Note the difference between wt and KO in the distribution of RGS5 and
DAG1 mRNAs. In some cases (p40/LRP), there was no change in the distribution of the RNA. There appears to be no change in the localization
of MAP2 mRNA. These images are representative of experiments reproduced at least three times in at least three different animals in each
group. Higher-magnification fields of the molecular layer of the hippocampus demonstrate the staining in the proximal dendrites emanating
from pyramidal cells. Scale bar equals 30 m (6 and 20) or 10 m (100).
tissue sources from hippocampus, cortex, or cerebellum sion (Figure 7; F  6.47; df  1,15, p  .05). In the CA1
region of the hippocampus, optical density measure-and that they represent young animals (15–35 days). It
is possible that these results may differ in a tissue- and ments detected less GR in the initial dendritic segment
contained within the stratum radiatum of KO comparedage-specific manner.
to wt animals. These data contrast with Western blot
data (Figure 6), indicating no differences in GR expres-Wild-Type and KO Differences
in the Immunolocalization of the FMRP sion levels in cortical synaptoneurosomes, which may
reflect a cortex versus hippocampus difference. In addi-Cargo Encoding GR
As an alternative approach to analyze possible expres- tion to GR, several other proteins were examined using
ICC including the  subunit of the GABAA receptor. Pre-sion differences, immunohistochemistry was performed
on CNS tissue from KO and wt mice to determine pat- liminary observations indicated that differences in the
dendritic localization of the proteins between KO andterns of protein localization for several FMRP cargoes.
GR immunoreactivity in dendrites was examined quan- wt animals for these proteins were not detected; hence,
these proteins were not examined in a quantitative man-titatively using densitometry by assessing the ratio of
the level of dendritic expression in stratum radiatum ner. Taken together, these data suggest a specific per-
turbation in GR expression in hippocampal dendritesversus the pyramidal cell layer. This revealed a statisti-
cally significant difference in the pattern of GR expres- as a result of FMRP absence.
In Vivo FMRP RNA Cargoes
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Figure 4. Differential ISH of FMRP RNA Cargoes between Wild-Type and Fmr1 KO Mice
ISH of six other FMRP cargoes was performed on wt or Fmr1 KO mice. Cerebellar (6) and hippocampal (20) fields demonstrate the
subcellular localization of each of the mRNAs tested here. For these mRNAs (CDK4, GABAA Rec,  subunit, -fodrin, p28/gankyrin, -adaptin,
and OCRL), there does not appear to be any overt change in the patterns of localization in either the cerebellum or hippocampus. Higher
power (100) fields of the hippocampus are consistent with this interpretation. Scale bar equals 30 m (6 and 20) or 10 m (100).
Discussion experimental differences unique to each report make
simple comparisons difficult. One important difference
is that this study is the first report of FMRP-associatedStudies elucidating the physiological role of FMRP have
recently focused on ascertaining the targets of the intrin- mRNAs isolated largely from neurons. Nonneuronal cells
in the whole brain outnumber neurons by 10-fold. It issic RNA binding activity of FMRP (Brown et al., 1998,
2001; Sung et al., 2000; Schaeffer et al., 2001; Darnell likely that within each cell type, FMRP acts as a binding
protein for a somewhat specific subset of mRNAs; differ-et al., 2001). By using an antibody to position a priming
oligo in close proximity to mRNAs sequestered in the ent brain regions may differ in this respect as well. These
differences would likely be more striking in lymphoblasts.FMRP mRNP complex, we have been able to efficiently
identify a subset of putative in vivo RNA substrates for One aspect of the current methodology is that it is poten-
tially applicable to varying isolated cell types. By doingFMRP.
After confirmation of FMRP binding using in vitro as- so, we may learn a great deal about the distinction be-
tween the physiological role FMRP plays in the specifi-sociation assays, we found that the proteins encoded
by RNA cargoes associating with FMRP fall into multiple cation of cell function.
The array platform used in the previous co-IP study,functional classes (Table 1). Cargoes encoding proteins
involved in synaptic plasticity and neuronal maturation Affymetrix MG-U74 microarrays, and the filter-based
macroarrays used for the APRA results provided littleappear to be a primary target of FMRP. These data
are consistent with earlier reports (Brown et al., 2001; overlap in corepresented genes. Affymetrix arrays em-
ploy short oligos throughout the array and input RNADarnell et al., 2001) that employed co-IP protocols from
mouse brain homogenates and lymphoblastoid cell lines probes may identify some targets as false positives due
to shared sequences. On the other hand, cDNA arraysor in vitro RNA selection from human parietal cortex to
identify putative FMRP targets. In contrast to the in vivo may not contain full-length cDNAs. Consequently, if
APRA generates cDNA 5 to the end of the sequenceantibody-based approach detailed here, a number of
Neuron
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Figure 5. Northern Blot and Real-Time PCR Analysis of Select FMRP Cargoes in Wild-Type and Fmr1 KO Mice
(A) Hippocampal total RNA from wt and KO mice was used to assess abundance differences for DAG1 and p40 mRNAs. Representative
photographs of Northern blots and their corresponding ethidium bromide staining are shown. Signal strength was determined by Imagequant
software and normalized for any loading differences. The statistical analysis of these data was accomplished with a two-sample t test assuming
equal variance: DAG1 (p  0.015), p40 (p  0.021).
(B) Hippocampal RNA from five wt mice and six KO was converted into cDNA and used for real-time PCR analysis. The primer sets used in
this analysis are shown (F, forward; R, reverse).
arrayed, it would be scored as a false negative upon not 4-fold enriched in IP probes versus total brain lysate
probes, resulting in a subset of 432 overlapping genes,array analysis. Nonetheless, we expanded our APRA
analysis by screening Research Genetics GF300 cDNA or 4%, common to both analyses. The subtraction of
these mRNAs will likely eliminate RNAs that can servemacroarrays in an effort to categorize more FMRP car-
goes and to facilitate a more complete comparison with as FMRP RNA cargoes from both high-abundance and
low-abundance classes. Interestingly, although Fmr1previously published data. Approximately 19% of the
cDNAs on the Neuroarrays hybridized with 1C3 APRAs. mRNA is not present on either the Neuroarray or GF300
array, it is present on the MG-U74 chip set but was notApproximately 60% of the subsets of candidates tested
here were determined to bind to FMRP directly in both detected among the co-IP FMRP-associated cargoes
under the more stringent criteria. As noted by Brown etFBA and UVX assays. Our continuing analysis of the
remaining clones will determine if this ratio is represen- al. (2001), their approach suffers from the potential to
remove bona fide FMRP cargoes. The synergy betweentative of the whole data set. If so, 11% of the gene
expressed on the Neuroarray would be positive in APRA the analyses presented in Brown et al. (2001), though
leading to a more conservative subset, would appearand the in vitro association assays. Brown et al. (2001)
used several levels of analysis to identify a core set of to magnify the loss of real FMRP targets such as Fmr1
mRNA. Of the top 80 differentially altered FMRP cargoesmRNAs associated with the FMRP antibody matrix. In
the first analysis, 26% of the expressed messages were (see Table 1 in Brown et al., 2001) identified by the co-
IP strategy, 17 of these were represented on the GF300enriched in wt IPs versus Fmr1 null mice IPs. A second
set of analysis was used to discard mRNAs that were macroarrays screened in the present study. APRA de-
Figure 6. Quantification of RNA Cargo West-
ern Blots for Total and Synaptoneurosome
Protein Preparations in Wild-Type and Fmr1
KO Mice
Protein lysates from total cortex or synapto-
neurosomes from the same pool of animals
were made. Western blots were initially
probed with antibodies to proteins encoded
by FMRP targets, and all specific stain inten-
sities were normalized to synaptophysin. For
each protein, the mean of at least six different
preparations is shown, for both total and syn-
aptoneurosomal protein samples. Ordinate:
ratio of KO to wt stain determined by densi-
tometry (NIH Image 1.62). The error bars rep-
resent the standard deviation.
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similar to Tensin [110429_at]; mRNA similar to acetylglu-
cosaminyl transferase [103276_at]). A 50% concor-
dance rate between these data sets suggests that both
procedures are able to identify at least a fraction of the
putative FMRP targets. The remaining eight corepre-
sented targets (adenylate cyclase 5&6 [probe set
ID#138967_i_at]; L-type calcium channel B3 [98483_at];
mRNA similar to MAP 1A and MAP 1B [116100_f_at]; KIA
AA1042 [96124_at]; SNF-1-related kinase [97429_at];
PI3 kinase regulatory subunit [102759_at]; Casein kinase
I 2 [96284_at]) were not detected by APRA analysis.
Ultimately, regardless of the selection methodology, the
number of false positives can only be determined by
the use of other assays showing a direct interaction with
FMRP.
The presence of a G-quartet in the human MAP1B
transcript (Darnell et al., 2001) and the morphological
similarity of hypomorphic Futsch/22C10 (Zhang et al.,
2001a) mutants to Drosophila models of FXS have
stressed its potential role in FXS pathogenesis. The most
recent annotation (http://www.netaffx.com) of the MG-
U74 chip set suggests that the mRNA originally identified
as “similar to MAP1A and MAP1B (116100_f_at)” by
Brown et al. (2001) is 98.74% similar to MAP1A. A clone
specific for MAP1B is present on the chip set but at
another location (99928_at), which was not identified as
one of the 432 putative cargoes of FMRP (see Supple-
mental Data for Brown et al., 2001). Based upon the
initial characterization of MAP1B as a FMRP cargo by
the co-IP method, Darnell et al. (2001) modeled the
MAP1B interaction with FMRP using a G-quartet se-
quence present in the 5-UTR of the human MAP1B
transcript. In Drosophila (Zhang et al., 2001a), the
MAP1B and FXR mutants share a common neuromuscu-
lar junction phenotype. Although a physical interaction
has been established with Futsch in an anti-dFXR co-
IP fraction, no direct interaction between the transcript
and dFXR has been demonstrated. In the present study,
APRA analysis of MAP1B (an an 9 kb mRNA) may have
been negative, as the GF300 arrays have 1 kb of se-
quence from the 3 end of the cDNA.
Also contributing to the differences between the iden-
tities of FMRP targets is the methodology itself. The co-
IP strategy will precipitate mRNAs not directly associ-
ated with FMRP due to its association with other RBPs.
Additionally, when the mRNP complexes are removed
Figure 7. Differential Distribution of the GR Protein in Wild-Type from the cell by creating a cellular lysate, the endoge-and Fmr1 KO Mice
nous salt concentrations are altered and FMRP cargoes
Wild-type (top) and KO (bottom) mouse brain stained forGR. Arrows
with low affinity may be lost while high-abundancepoint to greater dendritic staining in the CA1 region of wt mice
mRNAs from neurons or nonneuronal cells alike may(n  11) compared with KO (n  6). Pixel intensity derived from
specifically associate with RBPs. With regard to thedensitometric measurements comparing the staining intensity of the
initial dendritic segments of the stratum radiatum (SR) with adjacent APRA methodology, it may not amplify some mRNAs
cell bodies within the pyramidal cell layer (PCL) quantitatively con- that are not accessible for cDNA priming due to masking
firm the observation that KO mice have less GR in dendrites com- of mRNA sequences by other RBPs. Further, it may also
pared to wt (p  .05). Image analysis was performed using the prime mRNA sequences that are in proximity to the
AIS 3.0 software package (Imagine Research, Inc.) on identically
FMRP mRNP but not associated with FMRP itself.scanned grayscale digital images of each hippocampal section.
With these limitations in mind, we have presented theExaminers were blind to the genotype at the time of the analysis
largest study to date of FMRP targets confirmed by(400; scale bar equals 10 m).
conventional in vitro binding assays. Although in vitro
assays such as FBA and UVX assays assist us in veri-
tected eight, or50%, of these mRNAs positively (GRIN1 fying a direct mRNA-FMRP interaction, we cannot ex-
[probe set ID#113864_at]; IP3 receptor [94977_at]; Rab6- clude the possibility that some initial positives from the
associated GDI [104108_at]; Tesk1 [102033_at]; PI 4 ki- macroarray screening will not be confirmed by the sec-
ondary screens. There are several possible reasons.nase [104208_at]; -latroxin receptor [112497_at]; mRNA
Neuron
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First, the anti-FMRP mAb used in this study, 1C3, is from the endoplasmic reticulum, nuclear transport, and
known to minimally crossreact with FXR1P (Sittler et molecular chaperone-like activity (Dawson et al., 2002).
al., 1996). Anti-FXR1P APRA comparisons reveal some A scan of the other FMRP cargoes from Table 2 reveals
overlap, suggesting support for a hypothesized com- two other ubiquitin-proteasome pathway-related com-
pensatory function (Figure 1E). Qualitative patterns, ponents: the ubiquitin-conjugating enzyme E2A and or-
however, appear to be distinct from anti-FMRP APRA nithine decarboxylase antizyme. Although no antibodies
patterns of signal. Second, the known interaction of were available for these proteins, the presence of these
FMRP modulatory proteins such as NUFIP (Bardoni et components of the ubiquitin-proteasome pathway sug-
al., 1999) and CYFIP1/2 (Schenck et al., 2001) may place gests an avenue for future investigation.
the priming oligo on mRNP complexes in which the Glucocorticoid receptor  is a predominantly cyto-
mRNA sequence is in fact directly interacting with one plasmic, low-affinity receptor for corticosteroid hor-
of the other components of the RNP complex. Third, mones. Occupation of the mineralocorticoid receptor,
the phosphorylation status or some other modification the high-affinity corticosteroid receptor, in the presence
of FMRP may play a role in regulating the stability, local- of synaptic activity sustains steady, temporary in-
ization, or affinity of FMRP-RNA interactions. creases in electrical activity in the hippocampus. Brief
The affinity of FMRP for its RNA cargoes may ulti- occupation of GR slowly reverses this phenomenon
mately define the functional consequences of the inter- (Joels, 2001). In FXS, patients often display heightened
action. RBPs, showing low affinity and sequence speci- social anxiety and learning deficits that coincide with
ficity for RNA targets are often involved in the general increased levels of circulating corticosteroids (Hager-
packaging of the mRNP, while those demonstrating man and Sobesky, 1989; Wisbeck et al., 2000; Hessl et
high-level RNA binding are thought to be critical for al., 2002) and abnormal expression of glucocorticoid-
modulating specific aspects of gene control (Siomi et modulating proteins (Sun et al., 2001). The observed
al., 1996). The presence of a purine-quartet in a minority changes in GR distribution suggest diminished respon-
of the RNAs that bind to FMRP (23%, Table 2) suggests siveness to corticosteroids in the postsynaptic compart-
that this motif is not the sole determinant of RNA binding ment, which may disrupt corticosteroid feedback regu-
to FMRP. This is not surprising since FMRP contains lation and contribute to deficits in learning (Roozendaal,
three known RNA binding sites, each of which can be 2000).
envisioned to act independently or synergistically with Interestingly, some FXS victims exhibit signs of autis-
the others. tic behavior (Reiss and Freund, 1990; Feinstein and
In the postsynaptic compartment, the cooperative Reiss, 1998). Current estimates put the proportion of
regulation of multiple gene expression pathways by patients exhibiting significant symptoms at 15%–40%
RBPs may simplify the synchronization of a cellular re- (Rogers et al., 2001; Dykens and Volkmar, 1997). The
sponse. Indeed, recent reports have stressed how the chromosomal localization of each of the FMRP cargos
regulation of the architecture and stability of RNP com- was compared to the published genetic loci for genes
plexes contributes to the varied roles RBPs play in the associated with autism (Philippe et al., 1999; Collabora-
synchronization of biosynthesis, processing, transport, tive Linkage Study of Autism, 2001; Shao et al., 2002;
and translational control of RNAs (Keene, 2001). One International Molecular Genetic Study of Autism Consor-
prediction of this interaction is the disruption of the tium, 2001). Of the 81 FMRP cargos that were analyzed,
localization or abundance of mRNA cargoes of FMRP 15 mapped to autism loci (Table 1). While some of these
or their encoded proteins in the absence of FMRP. We loci are quite broad (e.g., 17q), most are more specific.
demonstrate here an apparent change in both the local- Given the cosegregation of these loci, it is intriguing to
ization and abundance of some of these mRNA cargoes speculate that polymorphisms in some of the FMRP
as well as the proteins they encode. Altered expression RNA cargos may contribute to both FXS and autism
patterns of the RNA cargoes and their encoded protein
clinical pathology and in other disorders associated with
suggest that the loss of FMRP in FXS may promote the
stereotypy, social impairment, and other autism charac-
accumulation of a series of spatially restricted structural
teristics.and signaling imbalances.
The identification of FMRP RNA cargoes gives rise to
speculation on how FMRP loss alters specific cellular Experimental Procedures
pathways. Consequently, we will limit our discussion to
Attachment of Single-Stranded Oligo to Antibodiesonly a subset of those RNA cargoes whose encoded
1C3 mAb (Devys et al., 1993), anti-Tau mAb (Sperber et al., 1995),protein levels were altered in the Fmr1 null mouse in
and mouse IgG1 (DAKO) were conjugated to either a short (84 nt)hippocampal immunocytochemistry or cortical Western
oligo (AAACGACGGCCGAATTCAAGCTTAGTGAATTGTAATACGAC
blots. TCACTATAGGG(AC)8A(N)15) or long (122 nt) oligo (AAACGACGGC
One FMRP cargo meeting this criteria is CDK4, which CGAATTCAAGCTTAGTGAATTGTAATACGACTCACTATAGGG(AC)27A
has recently been shown to be precipitated in a complex (N)15) as previously described (Zhang et al., 2001b). We have used
containing gankyrin, a non-ATPase subunit of the 26S short and long oligos with alternative linker sequences preceding
the (N)15 tail with similar results. In a separate series of experiments,proteasome, and the S6 ATPase (Dawson et al., 2002).
purification of mAb-DNA complex through a Centricon column pro-Both CDK4 and gankyrin RNAs are substrates of FMRP
duced similar results to the nonpurified mAb-DNA complex.(see Table 1). Within the 26 S proteasome, the S6 ATPase
of the regulator complex is one of six “base” ATPases
which belong to the AAA superfamily that are thought Cell Culture
to control 26S proteasomal function, peroxisomal bio- Cell culture was performed as described previously (Buchhalter et
al., 1990).genesis, membrane docking and fusion, protein egress
In Vivo FMRP RNA Cargoes
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Immunolabeling with mAb-DNA Complex and analyzed in a scintillation counter. Control reactions containing
only recombinant FMRP alone or mRNA alone were run simultane-Primary hippocampal cells were fixed in 4% paraformaldehyde in
PBS and permeabilized with 0.1% Triton X-100. Nonspecific binding ously (data not shown). All samples were compared to the known
interaction between FMRP protein and Fmr1 mRNA. 20% of FMRPof mAbs was minimized by blocking cells in 10% normal goat serum,
0.5% BSA, and 0.1% fish gelatin. 1C3 was added at 1/125 dilution binding was chosen as the cutoff for specificity since nothing below
20% was positive on the UV-crosslinking assay.and anti-tau was added at 1/150 dilution. After immunostaining, the
coverslips were stored at 4C in HEPES Buffered Saline until cDNA
synthesis. UV-Crosslinking Assay
Performed under exact conditions as FBA without RNAsin in 20 l
volumes containing 1  106 cpms of riboprobe were incubated withAPRA Reaction Conditions
1 mol FMRP protein for 20 min at 40C (Schaeffer et al., 2001)Coverslips visualized for immunofluorescence were prepared with
and UV crosslinked on ice for 10 min. UVX complexes were digestedCy3-conjugated goat anti-mouse Ab (Jackson ImmunoResearch).
with RNase A (25 g/ml) with 1 mM CaCl2. Samples were run on 7%Coverslips were rinsed twice in H2O. In situ transcription cDNA was
Tris-Acetate gels (Novex), dried, and apposed to a phosphorimagerperformed as previously described (Tecott et al., 1988). Newly syn-
screen for 72–96 hr. Incubation with increasing concentrations ofthesized cDNA was removed from the cells using 25 l of 0.1 N
unlabeled RNA could block the interaction between radiolabeledNaOH (freshly made) and transferred to a microcentrifuge tube. 10
RNAs and FMRP (data not shown).l of 1 M Tris (pH 7.2) was added to neutralize the NaOH, and
second-strand cDNA synthesis was performed as previously de-
scribed (Eberwine et al., 2001). Next, the DNA was removed from KO Mice and Wild-Type Controls
the antibody by cutting the double-stranded cDNA at the BamHI All subjects were derived from a sixth generation backcross (N6) of
restriction site located 5 to the T7 RNA polymerase promoter site. a 129  FVB  C57Bl/6 mouse described by the Dutch-Belgian
After restriction enzyme digestion, 10 g of tRNA carrier was added Consortium (1994) to JAX inbred C57Bl/6J mice.
and the solution was phenol/chloroform extracted and ethanol pre-
cipitated. The DNA pellet was dissolved in 10 l of H2O and taken In Situ Hybridization
through the aRNA amplification procedure. Second round aRNA Mice sections (P15) were prepared by standard paraffin-embedding
was radiolabeled with 33P-labeled radionuclides. Neuroarrays made protocols. Following deparaffinization and hydration, sections were
at the DNA Microarray Unit of the National Institute on Aging or permeabilized in 0.3% Triton X-100 in PBS for 20 min. Proteinase
Research Genetics GF300 filters were screened with the aRNA K was added at 7.5 g/ml and incubated at 37C for 10 min. Hybrid-
probe. A complete list of Neuroarray cDNAs is available online ization followed with all probes used at 2 ng/l of hybridization
(http://www.grc.nia.nih.gov/branches/rrb/dna/array.htm). Previous solution at 45C for 12–16 hr. Sections were extensively washed and
experiments in our laboratory have shown there to be sufficient taken through a TSA plus (NEN) protocol with minor modifications.
crosshybridization between the rat and human sequences to ensure Specific staining was assessed by challenge with unlabeled probe
a positive correlation between signal on the human array and the prior to hybridization of labeled probe and sense controls (data not
rat mRNAs. Background signal for array analyses was determined shown). No probe controls were used to assess background from
with Imagequant software (Molecular Dynamics) by averaging at tissue signal amplification kit.
least four of each of the randomly placed primer or empty spots on
the array within different grids for a total averaging of at least eight Northern Blotting
control spots. Raw images were quantitated by taking the volume Total RNA was isolated from P14–P16 hippocampi of KO (n  4) or
measurement of each signal. Each half of the array was analyzed wt mice (n  3) with Trizol Reagent, run on a 0.9% formaldehyde
independently and the average was used as the baseline signal for gel, and transferred to nylon membranes. Random-primed 32P
each gene on the Neuroarray. The data were not normalized in any probes were generated from plasmid cDNAs with the Rediprime
other fashion. Raw data for this analysis is available in Supplemental Kit (Amersham). Hybridization and washes followed manufacturer’s
Figure S2 at http://www.neuron.org/cgi/content/full/37/3/417/DC1. protocols.
Unique data spots with signal 150% above this background were
defined as positive signals. A subset (83) of the positive candidates Real-Time PCR
from 1C3 APRAs was screened in in vitro association assays. Standard curves for each primer set verified that a single amplifica-
tion product was obtained. KO and wt mice were sacrificed at P28.
Plasmid Vectors Hippocampi were dissected and RNA extracted. One microgram of
The DNA insert of the longest available IMAGE clone (80% were total RNA was used in a reverse transcription (RT) reaction (Super-
full-length) was PCR amplified with flanking primers, each of which script RTase, Invitrogen) in a final volume of 20 l. For relative real-
contained a RNA polymerase promoter site (T7, SP6, or T3). These time PCR, a 25 l reaction for each primer set was assembled using
templates were used to generate the riboprobes used in the FBA 2 SYBR Green PCR master mix (Applied Biosystems) along with
and UVX assays. For ISH studies, templates were digested with the 0.5 l of the RT reaction. A -actin primer set was used to normalize
appropriate restriction enzyme to yield 1 kb riboprobes with no the results for each sample tested. Primer sequences used in these
known sequence similarity to other isoforms or other mRNAs. Where studies can be found in Figure 5. Reactions were run on a Taqman
necessary (e.g., gankyrin), a noncross-reacting sequence (first 100 7700 (Applied Biosystems) and data analysis performed by the ac-
nt of coding region) was subcloned into a vector that was used to companying software.
generate isoform-specific riboprobes.
Western Blotting
Recombinant FMRP Protein for Western blotting was prepared from pooled cerebral
Tagged (6His and c-myc) recombinant FMRP was made by PCR cortices of KO or wt mice (P12–P15; Weiler et al., 1997). Twenty
amplification of a fragment from pSF1 and cloned into the NcoI and micrograms of each protein sample were separated by PAGE, blot-
NotI sites of pET 24d. After induction by IPTG in Bl-21 cells, bacteria ted, and immunostained using enhanced chemiluminescence. Den-
were harvested and protein was extracted using essentially the sitometry results for each lane were compared with staining for
Clontech protocol for Talon Resin. synaptophysin. Weighted median scores representing KO/wt ratios
from multiple total or synaptoneurosomal preparations were ana-
lyzed using a two-tailed t test. The hypothesized mean representingFilter Binding Assays
[-32P]GTP- or UTP-labeled RNAs (1  105 cpm; 1 fmol) were rena- wild-type expression for each protein was designated as a ratio of
1.0 and p values 0.05 were deemed significant. Antibodies andtured in Moine binding buffer and filter binding performed as pre-
viously described (Schaeffer et al., 2001), except all incubations their origin: GR, GRK2, GRK4, and gankyrin from Santa Cruz Bio-
technology; Cu/Zn SODs and CDK4 from Upstate Biotechnology;were at 40C. Samples were then transferred to vacuum apparatus
and applied to nitrocellulose (0.45 m pore size) and rinsed three -fodrin from J. Ursitti (University of Maryland); and p40/LRP from
U. Draegger (Harvard University).times with Moine binding buffer. Filters were air dried to completion
Neuron
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Immunohistochemistry for Proteins Encoded by RNA Cargos Darnell, R.B. (2001). Fragile X mental retardation protein targets G
quartet mRNAs important for neuronal function. Cell 107, 489–499.Mice (aged P15–P35) were anesthetized and transcardially perfused,
and brains were fixed, cryostat sectioned, and immunostained as Dawson, S., Apcher, S., Mee, M., Higashitsuji, H., Baker, R., Uhle,
described previously (Irwin et al., 2000). GR (Santa Cruz) was used S., Dubiel, W., Fujita, J., and Mayer, R. (2002). Gankyrin is an ankyrin-
at a 1:400 dilution. repeat oncoprotein that interacts with CDK4 kinase and the S6AT-
Pase of the 26S proteasome. J. Biol. Chem. 277, 10893–10902.
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